Cirka 6% af patienterne udviklede persisterende anti- natalizumab antistoffer (én positiv test bekræftet ved gentagelse af testen mindst 6 uger senere).
Persistent anti-natalizumab antibodies (one positive test reproducible on retesting at least 6 weeks later) developed in approximately 6% of patients.